Skip to main content
S&P 5007,718.60-0.38%DOW53,414.25-0.51%NASDAQ26,506.99-0.29%BTC$79,656.00-1.71%ETH$2,454.45-1.99%GOLD$4,477.20-1.38%OIL$91.22-0.09%
Smart Investors Daily
EN

NASDAQ · ENGN

enGene Holdings Inc.

Healthcare · Biotechnology

$1.82

Down-$0.01 (-0.55%)

Updated Sep 5, 2026, 3:14 AM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
455.64M
P/E ratio
-10.55
Dividend yield
0.00%
52-week range
$1.40 – $9.00
Volume
412.68K
Avg. volume
1.26M

Price performance

ENGN price history

1M range · 21 trading sessions · Daily adjusted prices

ENGN closed at $1.82 after 21 trading sessions, up 1.11% for the selected period.

Last close
$1.82
Period change
+1.11%
Period low
$1.69
Period high
$1.95
Daily close
View OHLC price history
ENGN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 4, 2026$1.82$1.835$1.78$1.82412.68K
Sep 3, 2026$1.90$1.91$1.80$1.83634.65K
Sep 2, 2026$1.84$1.9188$1.835$1.891.06M
Sep 1, 2026$1.84$1.8699$1.80$1.855657.38K
Aug 31, 2026$1.83$1.855$1.81$1.84291.28K
Aug 28, 2026$1.91$1.91$1.81$1.825447.14K
Aug 27, 2026$1.94$1.94$1.91$1.91252.12K
Aug 26, 2026$1.87$1.95$1.87$1.951.83M
Aug 25, 2026$1.82$1.886$1.815$1.871.01M
Aug 24, 2026$1.79$1.83$1.75$1.81642.5K
Aug 21, 2026$1.795$1.805$1.77$1.78242.73K
Aug 20, 2026$1.84$1.85$1.755$1.77368.44K
Aug 19, 2026$1.73$1.895$1.73$1.851.26M
Aug 18, 2026$1.70$1.74$1.69$1.72690.94K
Aug 17, 2026$1.72$1.73$1.69$1.70623.32K
Aug 14, 2026$1.69$1.73$1.66$1.70919.72K
Aug 13, 2026$1.71$1.728$1.68$1.69470.13K
Aug 12, 2026$1.82$1.83$1.69$1.701.67M
Aug 11, 2026$1.76$1.825$1.73$1.821.45M
Aug 10, 2026$1.78$1.785$1.74$1.75464.14K
Aug 7, 2026$1.81$1.8383$1.785$1.80351.63K

Latest ENGN news

The latest Smart Investors Daily articles mentioning ENGN.

Stock researchCompany · Overview

ENGN research

Overview

Company profile and research snapshot.

Company profile

enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$22.67
Implied upside
—
Analysts
—
ENGN recent ratings
DateFirmRatingTarget
Jun 18, 2026Morgan StanleyUnderweight—
Jun 16, 2026HC Wainwright & Co.Buy—
May 14, 2026UBSNeutral—
May 8, 2026HC Wainwright & Co.Buy—
May 8, 2026Piper SandlerNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 4, 2026

enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026

BOSTON & MONTREAL, August 04, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, August 11, 2026 at 11:00 AM ET featuring Neal Shore, MD, FACS (Carolina Urologic Research Center; Atlantic Urology Clinics). Dr. Shore will join management to provide insights into the evolving NMIBC treatment landscape and the various considerations dri

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By